Approach Phase 2b trial arm Duration 24 weeks Review Point Week 12 and 24 Notes METAOD006 (OPTIONS) used 24 weeks at oral doses 0.25, 0.5, or 1 mg/day in 502 obese adults
Water (Aqua), Aloe Barbadensis Leaf Juice, SD Alcohol 40-B (Alcohol Denat.), Alanine/Histidine/LysinePolypeptide Copper HCl, Panthenol, Arginine, Lactic Acid, Polyquaternium-16, Butylene Glycol, Biotin, PEG-12 Dimethicone, Glycerin, Pisum Sativum (Pea) Sprout Extract, Lavandula Angustifolia (Lavender) Flower Extract, Camellia Sinensis (Green Tea) Leaf Extract, Scutellaria Baicalensis Root Extract, Propanediol, Menthol, Pinanediol, Camphanediol, Polyquaternium-44, Amodimethicone, Hydrolyzed Quinoa, Coco-Caprylate, Isomalt, Xylitol, Glycine Soja (Soybean) Germ Extract, Triticum Vulgare (Wheat) Germ Extract, Guar Hydroxypropyltrimonium Chloride, Cetrimonium Chloride, Trideceth-12, Phenoxyethanol, Ethylhexylglycerin, Potassium Sorbate, Sodium Benzoate
This exceptional value comes from efficient operations without excessive overhead, direct relationships with reputable peptide suppliers, commitment to accessible wellness for our community, and transparent pricing with no hidden fees
The translational potential of AST as a therapeutic and preventive agent is critically evaluated, alongside its pharmacokinetic challenges, bioavailability, and safety profile in aging populations
These have been the focus of phase III clinical trials in patients with relapsed hodgkin's lymphoma (NCT00025636) [135, 136], and men with previously untreated germ cell cancer (NCT00003941) [137]
